CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients

Metastatic castration-resistant prostate cancer (mCRPC) patients with positive AR-V7 expression in their circulating tumour cells (CTCs) rarely derive benefit from abiraterone and enzalutamide. We performed a prospective, multicenter, single arm phase II clinical trial (CABA-V7) in mCRPC patients pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2022-12, Vol.177, p.33-44
Hauptverfasser:	Isebia, Khrystany T., Mostert, Bianca, Belderbos, Bodine P.S., Buck, Stefan A.J., Helmijr, Jean C.A., Kraan, Jaco, Beaufort, Corine M., Van, Mai N., Oomen - de Hoop, Esther, Sieuwerts, Anieta M., van IJcken, Wilfred F.J., van den Hout - van Vroonhoven, Mirjam C.G.N., Brouwer, Rutger W.W., Oole, Edwin, Hamberg, Paul, Haberkorn, Brigitte C.M., Helgason, Helgi H., de Wit, Ronald, Sleijfer, Stefan, Mathijssen, Ron H.J., Martens, John W.M., Jansen, Maurice P.H.M., van Riet, Job, Lolkema, Martijn P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Antagonists - therapeutic use Androgen receptor Biomarkers Biopsy Cabazitaxel Castration Chemotherapy CTC Deprivation Gene expression Genomics Humans Male Medical prognosis Metastases Metastasis Neoplastic Cells, Circulating - pathology NGS Nitriles - therapeutic use Patients Prostate cancer Prostate-Specific Antigen Prostatic Neoplasms, Castration-Resistant - pathology Protein Isoforms - genetics Receptors, Androgen - metabolism Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!